公开(公告)号：US20200054651A1

公开(公告)日：2020-02-20

申请号：US16482952

申请日：2018-02-02

申请人： The Regents of the University of California

发明人： Daniel K. Nomura ,  Elizabeth A. Moore ,  Carl C. Ward ,  Leslie A. Bateman ,  Tucker R. Huffman ,  David K. Miyamoto ,  Jessica Spradlin

IPC分类号： A61K31/585 ,  A61K31/357 ,  A61K31/404 ,  A61K31/167 ,  A61K31/245 ,  A61K31/341 ,  A61K31/165 ,  A61K31/36 ,  A61K31/495 ,  A61K31/40 ,  A61K31/5375 ,  A61K31/445 ,  A61K31/16 ,  A61P35/00 ,  C12N9/16

摘要： Disclosed herein, inter alia, are compositions and methods useful for modulating PPP2R1 A and for the treatment of cancer.

公开(公告)号：US10456377B2

公开(公告)日：2019-10-29

申请号：US15490011

申请日：2017-04-18

申请人： St. Renatus, LLC

发明人： Mark D. Kollar

IPC分类号： A61K31/4164 ,  A61K9/00 ,  A61K31/245 ,  A61K31/4174 ,  A61K9/14 ,  A61M19/00

摘要： The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.

公开(公告)号：US20190292135A1

公开(公告)日：2019-09-26

申请号：US16297190

申请日：2019-03-08

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Brent R. Stockwell ,  Rachid Skouta ,  Scott Dixon

IPC分类号： C07C229/56 ,  C07C229/60 ,  C07D401/12 ,  C07D239/26 ,  C07D213/38 ,  A61K45/06 ,  A61K31/196 ,  A61K31/505 ,  C07C255/58 ,  A61K31/245 ,  C07C271/24

摘要： The present invention provides, inter alia, a compound having the structure of Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.

公开(公告)号：US10391074B2

公开(公告)日：2019-08-27

申请号：US14098633

申请日：2013-12-06

申请人： Sambria Pharmaceuticals, LLC

发明人： Michael Harvey Greenspan

IPC分类号： A61K31/196 ,  A61K31/10 ,  A61K31/08 ,  A61K45/06 ,  A61K31/167 ,  A61K31/245 ,  A61K31/573 ,  A61K9/00

摘要： A composition for pain relief including synergistically effective amounts of an amino benzoate local anesthetic, methylsulfonylmethane (MSM), and ethoxydiglycol. A method of treating pain, by applying the composition to skin in an area of pain, and blocking nerve signals. A method of improving range of motion in an individual, by applying the composition to skin, relieving pain, and allowing the individual to have an improved range of motion at an area of pain.

公开(公告)号：US20190247377A1

公开(公告)日：2019-08-15

申请号：US16396071

申请日：2019-04-26

申请人： The Children's Medical Center Corporation

发明人： Charles Berde ,  Daniel S. Kohane

IPC分类号： A61K31/445 ,  A61K31/52 ,  A61P43/00 ,  A61K31/519 ,  A61K31/245 ,  A61K31/137 ,  A61K9/00

CPC分类号： A61K31/445 ,  A61K9/0019 ,  A61K31/137 ,  A61K31/245 ,  A61K31/519 ,  A61K31/52 ,  A61P43/00 ,  A61K2300/00

摘要： Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.

公开(公告)号：US20190247336A1

公开(公告)日：2019-08-15

申请号：US15999705

申请日：2018-08-20

申请人： Acorda Therapeutics, Inc.

发明人： Manoj Maniar

IPC分类号： A61K31/165 ,  A61K9/00 ,  A61K45/06 ,  A61K31/325 ,  A61K31/245 ,  A61K31/045 ,  A61K31/18 ,  A61K31/17 ,  A61K31/167 ,  A61K31/16 ,  A61K31/24

CPC分类号： A61K31/165 ,  A61K9/0019 ,  A61K31/045 ,  A61K31/16 ,  A61K31/167 ,  A61K31/17 ,  A61K31/18 ,  A61K31/24 ,  A61K31/245 ,  A61K31/325 ,  A61K45/06 ,  A61K2300/00

摘要： Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.

公开(公告)号：US10330670B2

公开(公告)日：2019-06-25

申请号：US14437925

申请日：2013-10-24

申请人： TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY ,  JAPAN INNOVATIVE THERAPEUTICS, INC.

发明人： Hiroshi Matsuda ,  Akane Tanaka

IPC分类号： G01N33/573 ,  G01N33/53 ,  C12Q1/25 ,  G01N33/50 ,  A61K45/00 ,  A61K31/352 ,  G01N33/68 ,  A61K45/06 ,  A61K9/00 ,  A61K31/245 ,  A61K47/10 ,  C07K16/40

摘要： Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.

公开(公告)号：US10233171B2

公开(公告)日：2019-03-19

申请号：US15442475

申请日：2017-02-24

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Brent R. Stockwell ,  Scott J. Dixon ,  Rachid Skouta

IPC分类号： C07D213/74 ,  A61K31/47 ,  C07D401/12 ,  C07D309/14 ,  C07C255/58 ,  C07D213/80 ,  C07C271/16 ,  C07C271/24 ,  C07C271/28 ,  C07C205/57 ,  C07C205/58 ,  C07C211/50 ,  C07D239/26 ,  C07C229/60 ,  C07C233/54 ,  C07C237/30 ,  C07D295/088 ,  C07D211/58 ,  C07D295/30 ,  C07D213/36 ,  A61K31/245 ,  A61K31/325 ,  A61K31/351 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/5375 ,  A61K45/06 ,  C07C69/78 ,  C07D295/192 ,  A61K31/27 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4468 ,  A61K31/505 ,  A61K31/506 ,  C07C225/22 ,  C07D239/42

摘要： The present invention provides, inter alia, a compound having the structure: Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.

公开(公告)号：US10226496B2

公开(公告)日：2019-03-12

申请号：US15914064

申请日：2018-03-07

申请人： Ronald D. Sekura ,  Roscoe M. Moore

发明人： Ronald D. Sekura ,  Roscoe M. Moore

IPC分类号： A61K36/00 ,  A61K36/185 ,  A61K31/352 ,  A61K31/573 ,  A61K31/085 ,  A61K31/245 ,  A61K31/047 ,  A61K31/235 ,  A61K31/045 ,  A61K36/61 ,  A61K9/00 ,  A61K45/06 ,  A61K31/05 ,  A61K31/12 ,  A61K31/618 ,  A61K47/12 ,  A61K9/06 ,  A61K9/08 ,  A61K47/44 ,  A61K8/49 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q19/00 ,  A61P17/06

摘要： A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.

公开(公告)号：US20190060426A1

公开(公告)日：2019-02-28

申请号：US16171465

申请日：2018-10-26

申请人： THE CORPORATION OF MERCER UNIVERSITY

发明人： Martin J. D'SOUZA

IPC分类号： A61K39/00 ,  A61K39/155 ,  A61K9/16 ,  A61K9/51 ,  A61K31/245 ,  A61K31/46 ,  A61K31/5383 ,  A61K31/7036 ,  A61K31/7048 ,  C12N15/88 ,  C12N7/00 ,  C12N5/071 ,  A61K39/165 ,  A61K9/00 ,  A61K39/095 ,  A61K31/727 ,  A61K31/7088 ,  A61K48/00

摘要： A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.